New York State Common Retirement Fund Has $157.85 Million Holdings in Danaher Corporation $DHR

New York State Common Retirement Fund decreased its position in Danaher Corporation (NYSE:DHR) by 6.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 796,185 shares of the conglomerate’s stock after selling 50,500 shares during the period. New York State Common Retirement Fund owned approximately 0.11% of Danaher worth $157,852,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of DHR. Norges Bank acquired a new stake in Danaher during the second quarter worth approximately $1,979,503,000. Viking Global Investors LP grew its position in shares of Danaher by 543.9% during the 2nd quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate’s stock worth $574,351,000 after buying an additional 2,455,994 shares during the period. Generation Investment Management LLP lifted its position in shares of Danaher by 56.2% during the 2nd quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock valued at $980,914,000 after acquiring an additional 1,787,522 shares during the period. Primecap Management Co. CA lifted its position in shares of Danaher by 924.2% during the 2nd quarter. Primecap Management Co. CA now owns 1,239,320 shares of the conglomerate’s stock valued at $244,815,000 after acquiring an additional 1,118,318 shares during the period. Finally, Vanguard Group Inc. boosted its stake in Danaher by 1.3% during the second quarter. Vanguard Group Inc. now owns 60,769,587 shares of the conglomerate’s stock worth $12,004,424,000 after acquiring an additional 788,499 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Teri List sold 3,298 shares of Danaher stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total transaction of $746,997.00. Following the sale, the director directly owned 20,762 shares in the company, valued at $4,702,593. The trade was a 13.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Georgeann Couchara sold 5,174 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the transaction, the senior vice president owned 2,625 shares in the company, valued at approximately $552,352.50. The trade was a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 30,248 shares of company stock valued at $6,609,663 in the last ninety days. 11.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on DHR. Robert W. Baird set a $247.00 price objective on shares of Danaher in a report on Wednesday, October 22nd. Jefferies Financial Group reaffirmed a “buy” rating and set a $265.00 price target on shares of Danaher in a research note on Wednesday. TD Cowen reiterated a “buy” rating on shares of Danaher in a report on Wednesday, January 7th. Redburn Partners set a $220.00 target price on Danaher in a research report on Wednesday, October 8th. Finally, Argus set a $265.00 target price on Danaher in a report on Wednesday, January 14th. Twenty equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, Danaher currently has an average rating of “Moderate Buy” and a consensus price target of $252.70.

Danaher Stock Down 5.0%

DHR stock opened at $224.00 on Thursday. The firm has a market capitalization of $158.22 billion, a PE ratio of 46.19, a P/E/G ratio of 3.59 and a beta of 0.89. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $242.80. The stock’s 50 day moving average is $230.83 and its 200-day moving average is $213.77.

Danaher (NYSE:DHR) last released its quarterly earnings results on Wednesday, January 28th. The conglomerate reported $2.23 EPS for the quarter, beating analysts’ consensus estimates of $2.14 by $0.09. The business had revenue of $6.84 billion during the quarter, compared to analyst estimates of $6.79 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.Danaher’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.14 EPS. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. Sell-side analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, December 26th. Danaher’s payout ratio is presently 26.39%.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q4 results beat consensus: Danaher reported $2.23 EPS and revenue of $6.84B (y/y +4.5%), topping estimates and showing broad-based growth across segments. Danaher Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Bioprocessing and diagnostics momentum and strong free cash flow were highlighted on the call, supporting operational quality and potential upside as pharma spending recovers. Danaher Corp (DHR) Q4 2025 Earnings Call Highlights
• Positive Sentiment: Analysts remain constructive: several firms reiterated Buy/outperform views, pointing to core performance and bioprocessing upside despite near-term headwinds. Danaher: Solid Core Performance and Bioprocessing Upside Support Buy Rating into 2026
• Neutral Sentiment: FY‑2026 EPS guidance set to $8.35–$8.50, effectively in line with the Street (consensus ~8.42), so guidance neither materially beats nor misses expectations. Danaher forecasts 2026 profit line with estimates on pharma spending recovery
• Neutral Sentiment: Management tone: the company expects a gradual improvement in pharma and other end markets but signaled uneven recovery and some caution around academic research spending. Danaher Expects Gradual Improvement In End-Market Conditions
• Negative Sentiment: Market reaction: despite the beat, investors sold shares after the outlook and cautious commentary were viewed as merely in-line — weighing on the stock in premarket and intraday trading. Danaher stock drops after Q4 2025 results

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.